Endpoints News 生物医药· Nicole DeFeudis·· 26 天前AI 评分32
#ESMO26: 辉瑞在肺癌晚期失败后寻求新出路,BioNTech与百时美施贵宝展现早期活性
#ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Bristol Myers show early activity
AI 导读
辉瑞正试图在肺癌晚期治疗失利后寻找新方向,其针对早期线患者的事后分析显示潜在积极信号。与此同时,BioNTech和百时美施贵宝在早期研究中展现出活性。
正文
MADRID — Pfizer is moving past its late-stage loss in non-small cell lung cancer, pointing to a post-hoc analysis of earlier-line patients who appear to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news